Coagulation Studies

Background

• Coagulation studies assess the function of the coagulation cascade and guide management of bleeding, anticoagulation, and coagulopathy in the ED
• Standard panel includes: PT (prothrombin time), INR (international normalized ratio), and PTT/aPTT (activated partial thromboplastin time)
• Additional coagulation-related tests include: fibrinogen, D-dimer, thrombin time (TT), mixing studies, and anti-factor Xa levels
• Collected in a citrate (blue top) tube — tube must be filled to the line; underfilling causes falsely prolonged results due to excess citrate
• Evidence suggests coagulation panels are frequently over-ordered in the ED with limited impact on management in many clinical scenarios

Components

PT / INR

• Assesses: Extrinsic and common pathways (Factors VII, X, V, II, fibrinogen)
• Normal PT: ~11–13.5 seconds (lab-dependent)
• Normal INR: 0.8–1.2
• Primary uses:
  • Monitor warfarin therapy (target INR 2.0–3.0 for most indications; 2.5–3.5 for mechanical valves)
  • Assess liver synthetic function (component of MELD score)
  • Screen for DIC, vitamin K deficiency
  • Pre-thrombolytic assessment
• Causes of prolonged PT/INR:
  • Warfarin use
  • Vitamin K deficiency (malnutrition, prolonged antibiotics, cholestasis)
  • Liver disease/hepatic failure
  • DIC
  • Factor VII deficiency (isolated PT prolongation with normal PTT)
  • Supratherapeutic anticoagulation

PTT / aPTT

• Assesses: Intrinsic and common pathways (Factors XII, XI, IX, VIII, X, V, II, fibrinogen)
• Normal aPTT: ~25–35 seconds (lab-dependent)
• Primary uses:
  • Monitor unfractionated heparin (UFH) therapy
  • Screen for hemophilia (Factor VIII or IX deficiency)
  • Evaluate unexplained bleeding
  • Detect lupus anticoagulant (paradoxically causes thrombosis, not bleeding)
• Causes of prolonged PTT:
  • Heparin use (most common in ED)
  • Hemophilia A (Factor VIII deficiency) or B (Factor IX deficiency)
  • Von Willebrand Disease
  • DIC
  • Direct thrombin inhibitors (dabigatran, argatroban, bivalirudin)
  • Lupus anticoagulant
  • Severe liver disease

Fibrinogen

• Normal: 200–400 mg/dL
• Critical value: < 100 mg/dL (high bleeding risk)
• Acute phase reactant — may be falsely normal or elevated in early DIC or inflammatory states
• Decreased in: DIC (consumptive), massive transfusion (dilutional), severe liver disease, dysfibrinogenemia, thrombolytic therapy
• Key component of DIC screening panel
• Target > 150–200 mg/dL in active hemorrhage and obstetric emergencies

D-Dimer

• Fibrin degradation product; marker of fibrinolysis
• Normal: < 500 ng/mL (age-adjusted cutoff: age × 10 ng/mL for patients > 50 years)
• Primary ED uses:
  • Rule out PE and DVT (high sensitivity, low specificity; useful only with low-to-moderate pretest probability)
  • Component of DIC diagnostic scoring (ISTH criteria)
• Elevated in: VTE, DIC, sepsis, trauma, surgery, pregnancy, malignancy, inflammation, post-thrombolysis — very nonspecific

Thrombin Time (TT)

• Measures conversion of fibrinogen to fibrin (final common step)
• Normal: ~14–19 seconds
• Prolonged by: heparin, direct thrombin inhibitors (dabigatran), hypofibrinogenemia (< 100 mg/dL), dysfibrinogenemia, elevated fibrin degradation products
• Useful for detecting heparin contamination of specimens and confirming dabigatran effect

Anti-Factor Xa Level

• Uses:
  • Monitor LMWH (enoxaparin) — therapeutic range 0.5–1.0 IU/mL (treatment dose); 0.2–0.5 IU/mL (prophylactic)
  • Monitor UFH (increasingly used as alternative to aPTT)
  • Some assays can estimate DOAC (rivaroxaban, apixaban) drug levels, but availability is limited
• Draw 4 hours post-dose for LMWH (peak level)

Interpretation Patterns

PT/INR	PTT	Fibrinogen	D-Dimer	Likely Diagnosis
↑	Normal	Normal	Normal	Warfarin, vitamin K deficiency, early liver disease, Factor VII deficiency
Normal	↑	Normal	Normal	Heparin, hemophilia A/B, vWD, lupus anticoagulant, Factor XI/XII deficiency
↑	↑	Normal	Normal	Common pathway defect (Factor X, V, II), liver disease, supratherapeutic anticoagulation, direct thrombin inhibitor
↑	↑	↓	↑↑	DIC (consumptive coagulopathy)
↑	↑	↓	Normal/↑	Severe liver failure, massive transfusion (dilutional coagulopathy)
Normal	Normal	Normal	↑	VTE, inflammation, infection, malignancy, post-surgical (D-dimer alone is nonspecific)

Evaluation

Appropriate ED Indications

• Active hemorrhage or hemodynamic instability from suspected bleeding
• Patients on anticoagulants (warfarin, heparin, DOACs) presenting with bleeding, trauma, or requiring urgent procedures
• Suspected DIC (order PT, PTT, fibrinogen, D-dimer, platelets)
• Severe sepsis/septic shock
• Liver failure or suspected hepatic coagulopathy
• Pre-thrombolytic assessment (stroke, STEMI, massive PE)
• Unexplained petechiae, purpura, or mucosal bleeding
• Massive transfusion protocol activation

===Low-Yield Indications (Consider NOT Ordering)===

• Routine preoperative screening in patients without bleeding history
• Chest pain / ACS workup without planned anticoagulation or thrombolysis
• Simple laceration repair
• Before initiating anticoagulation in patients with no clinical bleeding
• Routine admission screening in well-appearing patients

Management

Warfarin Reversal (Elevated INR)

• INR 4.5–10, no bleeding: Hold warfarin; consider oral vitamin K 1–2.5 mg
• INR > 10, no bleeding: Hold warfarin; oral vitamin K 2.5–5 mg
• Serious/life-threatening bleeding (any INR): IV vitamin K 10 mg PLUS 4-factor PCC (Kcentra; dose based on INR and weight) — do not wait for vitamin K effect; PCC works within minutes
• FFP (15–20 mL/kg) is second-line if PCC is unavailable — slower onset, larger volume

Heparin Reversal

• UFH: Protamine sulfate (1 mg per 100 units of heparin given in last 2–3 hours; max 50 mg)
• LMWH: Protamine partially reverses (~60%); 1 mg per 1 mg enoxaparin given in last 8 hours

DOAC Reversal

• Dabigatran: Idarucizumab (Praxbind) 5 g IV — specific reversal agent
• Rivaroxaban/Apixaban: Andexanet alfa (Andexxa) if available; otherwise 4-factor PCC (50 units/kg) as an off-label alternative
• Activated charcoal if ingestion within 2 hours

DIC Management

• Treat underlying cause (sepsis, malignancy, obstetric emergency)
• Transfuse as indicated: platelets (if < 10,000 or < 50,000 with bleeding), cryoprecipitate (if fibrinogen < 100–150 mg/dL), FFP (if PT/PTT significantly prolonged with bleeding)
• Do NOT give heparin empirically — consider only in DIC with predominant thrombotic phenotype in consultation with hematology

Disposition

• Coagulopathy with active bleeding requires admission, often to ICU
• Supratherapeutic INR without bleeding may be managed with dose adjustment and close follow-up if patient is reliable
• New unexplained coagulopathy warrants admission for workup
• Patients on anticoagulants after trauma (especially head trauma) may require prolonged observation and repeat imaging regardless of initial coagulation results

See Also

• CBC
• DIC
• Warfarin
• Heparin
• Pulmonary Embolism
• DVT
• Hemophilia
• Von Willebrand disease
• Massive Transfusion
• Peripheral blood smear
• Liver failure

External Links

• Interpretation of Blood Clotting Studies and Values - StatPearls
• Coagulation Tests - EMCrit IBCC
• Emergency medicine misconceptions: utility of routine coagulation panels - Am J Emerg Med 2021
• 2020 ACC Expert Consensus on Management of Bleeding on Oral Anticoagulants - JACC 2020